Literature DB >> 26706536

Anti-biofilm activity of chitosan gels formulated with silver nanoparticles and their cytotoxic effect on human fibroblasts.

M Pérez-Díaz1, E Alvarado-Gomez1, M Magaña-Aquino2, R Sánchez-Sánchez3, C Velasquillo3, C Gonzalez1, A Ganem-Rondero4, G Martínez-Castañon5, N Zavala-Alonso5, F Martinez-Gutierrez1.   

Abstract

The development of multi-species biofilms in chronic wounds is a serious health problem that primarily generates strong resistance mechanisms to antimicrobial therapy. The use of silver nanoparticles (AgNPs) as a broad-spectrum antimicrobial agent has been studied previously. However, their cytotoxic effects limit its use within the medical area. The purpose of this study was to evaluate the anti-biofilm capacity of chitosan gel formulations loaded with AgNPs, using silver sulfadiazine (SSD) as a standard treatment, on strains of clinical isolates, as well as their cytotoxic effect on human primary fibroblasts. Multi-species biofilm of Staphylococcus aureus oxacillin resistant (MRSA) and Pseudomonas aeruginosa obtained from a patient with chronic wound infection were carried out using a standard Drip Flow Reactor (DFR) under conditions that mimic the flow of nutrients in the human skin. Anti-biofilm activity of chitosan gels and SSD showed a log-reduction of 6.0 for MRSA when chitosan gel with AgNPs at a concentration of 100 ppm was used, however it was necessary to increase the concentration of the chitosan gel with AgNPs to 1000 ppm to get a log-reduction of 3.3, while the SSD showed a total reduction of both bacteria in comparison with the negative control. The biocompatibility evaluation on primary fibroblasts showed better results when the chitosan gels with AgNPs were tested even in the high concentration, in contrast with SSD, which killed all the primary fibroblasts. In conclusion, chitosan gel formulations loaded with AgNPs effectively prevent the formation of biofilm and kill bacteria in established biofilm, which suggest that chitosan gels with AgNPs could be used for prevention and treatment of infections in chronic wounds. The statistic significance of the biocompatibility of chitosan gel formulations loaded with AgNPs represents an advance; however further research and development are necessary to translate this technology into therapeutic and preventive strategies.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biofilm; CDC reactor; Chitosan; Chronic wound infection; DFR reactor; Primary fibroblasts; Pseudomonas aeruginosa; Silver nanoparticles; Staphylococcus aureus

Mesh:

Substances:

Year:  2015        PMID: 26706536     DOI: 10.1016/j.msec.2015.11.036

Source DB:  PubMed          Journal:  Mater Sci Eng C Mater Biol Appl        ISSN: 0928-4931            Impact factor:   7.328


  20 in total

Review 1.  Chitosan's biological activity upon skin-related microorganisms and its potential textile applications.

Authors:  Eduardo M Costa; Sara Silva; Mariana Veiga; Freni K Tavaria; Maria M Pintado
Journal:  World J Microbiol Biotechnol       Date:  2018-06-13       Impact factor: 3.312

2.  Apoptosis induction in lung and prostate cancer cells through silver nanoparticles synthesized from Pinus roxburghii bioactive fraction.

Authors:  Reena Kumari; Adesh K Saini; Amit Kumar; Reena V Saini
Journal:  J Biol Inorg Chem       Date:  2019-10-23       Impact factor: 3.358

Review 3.  Antibacterial and antibiofilm potential of silver nanoparticles against antibiotic-sensitive and multidrug-resistant Pseudomonas aeruginosa strains.

Authors:  Davi de Lacerda Coriolano; Jaqueline Barbosa de Souza; Elias Vicente Bueno; Sandrelli Meridiana de Fátima Ramos Dos Santos Medeiros; Iago Dillion Lima Cavalcanti; Isabella Macário Ferro Cavalcanti
Journal:  Braz J Microbiol       Date:  2020-11-24       Impact factor: 2.476

Review 4.  The Expanded Role of Chitosan in Localized Antimicrobial Therapy.

Authors:  Lisa Myrseth Hemmingsen; Nataša Škalko-Basnet; May Wenche Jøraholmen
Journal:  Mar Drugs       Date:  2021-12-08       Impact factor: 5.118

5.  Evaluation of a 2-aminoimidazole variant as adjuvant treatment for dermal bacterial infections.

Authors:  G Logan Draughn; C Leigh Allen; Patricia A Routh; Maria R Stone; Kelly R Kirker; Laura Boegli; Ryan M Schuchman; Keith E Linder; Ronald E Baynes; Garth James; Christian Melander; Angela Pollard; John Cavanagh
Journal:  Drug Des Devel Ther       Date:  2017-01-16       Impact factor: 4.162

6.  Silver-pig skin nanocomposites and mesenchymal stem cells: suitable antibiofilm cellular dressings for wound healing.

Authors:  Mario Alberto Pérez-Díaz; Phaedra Silva-Bermudez; Binisa Jiménez-López; Valentín Martínez-López; Yaaziel Melgarejo-Ramírez; Ana Brena-Molina; Clemente Ibarra; Isabel Baeza; M Esther Martínez-Pardo; M Lourdes Reyes-Frías; Erik Márquez-Gutiérrez; Cristina Velasquillo; Gabriel Martínez-Castañon; Fidel Martinez-Gutierrez; Roberto Sánchez-Sánchez
Journal:  J Nanobiotechnology       Date:  2018-01-10       Impact factor: 10.435

7.  In vitro and in vivo evaluation of biologically synthesized silver nanoparticles for topical applications: effect of surface coating and loading into hydrogels.

Authors:  Aml I Mekkawy; Mohamed A El-Mokhtar; Nivien A Nafady; Naeima Yousef; Mostafa A Hamad; Sohair M El-Shanawany; Ehsan H Ibrahim; Mahmoud Elsabahy
Journal:  Int J Nanomedicine       Date:  2017-01-23

8.  Combined Activity of Colloid Nanosilver and Zataria Multiflora Boiss Essential Oil-Mechanism of Action and Biofilm Removal Activity.

Authors:  Maryam Shirdel; Hossein Tajik; Mehran Moradi
Journal:  Adv Pharm Bull       Date:  2017-12-31

9.  Synergistic Anti-MRSA Activity of Cationic Nanostructured Lipid Carriers in Combination With Oxacillin for Cutaneous Application.

Authors:  Ahmed Alalaiwe; Pei-Wen Wang; Po-Liang Lu; Ya-Ping Chen; Jia-You Fang; Shih-Chun Yang
Journal:  Front Microbiol       Date:  2018-07-04       Impact factor: 5.640

Review 10.  Chitosan based metallic nanocomposite scaffolds as antimicrobial wound dressings.

Authors:  Annapoorna Mohandas; S Deepthi; Raja Biswas; R Jayakumar
Journal:  Bioact Mater       Date:  2017-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.